These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
444 related articles for article (PubMed ID: 29129561)
1. Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: A 16-Year Australian Single Centre Experience. Nogic J; Koh Y; Bak M; Gooley RP; Meredith IT; McCormick LM Heart Lung Circ; 2018 Dec; 27(12):1446-1453. PubMed ID: 29129561 [TBL] [Abstract][Full Text] [Related]
2. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a systematic review of published studies. Alam M; Dokainish H; Lakkis N J Interv Cardiol; 2006 Aug; 19(4):319-27. PubMed ID: 16881978 [TBL] [Abstract][Full Text] [Related]
3. Long-term clinical follow-up of patients undergoing percutaneous alcohol septal reduction for symptomatic obstructive hypertrophic cardiomyopathy. Fortunato de Cano S; Nicolas Cano M; de Ribamar Costa J; Alves Pinheiro J; Bellio de Mattos Barretto R; Costa de Souza Le Bihan D; Abizaid A; Sousa A; Eduardo Sousa J Catheter Cardiovasc Interv; 2016 Nov; 88(6):953-960. PubMed ID: 27143093 [TBL] [Abstract][Full Text] [Related]
4. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: Acute results and three-year noninvasive follow-up in 18 patients. Guo H; Wang J; Chen J; Shan J; Lee JD; Ueda T Can J Cardiol; 2004 Jun; 20(8):779-82. PubMed ID: 15229758 [TBL] [Abstract][Full Text] [Related]
5. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients. Seggewiss H; Gleichmann U; Faber L; Fassbender D; Schmidt HK; Strick S J Am Coll Cardiol; 1998 Feb; 31(2):252-8. PubMed ID: 9462563 [TBL] [Abstract][Full Text] [Related]
6. Alcohol septal ablation in hypertrophic cardiomyopathy utilizing a longitudinal 17-year study (mean 10.8). Observation follow-ups taken at a single medical centre. Wojtarowicz A; Kornacewicz-Jach Z Cardiol J; 2017; 24(2):125-130. PubMed ID: 27734458 [TBL] [Abstract][Full Text] [Related]
7. Percutaneous alcohol septal ablation for hypertrophic obstructive cardiomyopathy: technical review and long-term clinical and echocardiographic outcomes. Leal S; Galeote G; Jiménez-Valero S; Sánchez-Recalde A; Salinas P; Ruiz AS; Orbe LC; Dominguéz F; Moreno R; López-Sendón JL Rev Port Cardiol; 2012 May; 31(5):363-71. PubMed ID: 22482474 [TBL] [Abstract][Full Text] [Related]
8. Predictors of Outcome After Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: An Echocardiography and Cardiovascular Magnetic Resonance Imaging Study. Lu M; Du H; Gao Z; Song L; Cheng H; Zhang Y; Yin G; Chen X; Ling J; Jiang Y; Wang H; Li J; Huang J; He Z; Zhao S Circ Cardiovasc Interv; 2016 Mar; 9(3):e002675. PubMed ID: 26884612 [TBL] [Abstract][Full Text] [Related]
9. Early remodelling of left ventricle and improvement of myocardial performance in patients after percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy. Veselka J; Honek T Int J Cardiol; 2003 Mar; 88(1):27-32. PubMed ID: 12659981 [TBL] [Abstract][Full Text] [Related]
10. A novel approach in the use of radiofrequency catheter ablation of septal hypertrophy in hypertrophic obstructive cardiomyopathy. Shelke AB; Menon R; Kapadiya A; Yalagudri S; Saggu D; Nair S; Narasimhan C Indian Heart J; 2016; 68(5):618-623. PubMed ID: 27773399 [TBL] [Abstract][Full Text] [Related]
11. Gender Disparities in Clinical Outcome After Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy in the Chinese Han Population: A Cohort Study. Wang Y; Zhao HW; Wang CF; Meng QK; Cui CS; Zhang XJ; Zhu Y; Fan CY; Luo DF; Chen BJ; Luan B; Hou AJ Heart Lung Circ; 2020 Dec; 29(12):1856-1864. PubMed ID: 32611501 [TBL] [Abstract][Full Text] [Related]
12. Short- and long-term outcome after alcohol septal ablation in obstructive hypertrophic cardiomyopathy: Experience of a reference center. Aguiar Rosa S; Fiarresga A; Galrinho A; Cacela D; Ramos R; de Sousa L; Gonçalves A; Bernardes L; Patrício L; Branco LM; Ferreira RC Rev Port Cardiol (Engl Ed); 2019 Jul; 38(7):473-480. PubMed ID: 31495717 [TBL] [Abstract][Full Text] [Related]
13. Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy; The Chinese experience in 119 patients from a single center. Li ZQ; Cheng TO; Zhang WW; Qiao SB; Zhao LY; Jin YZ; Guan RM; Liu L Int J Cardiol; 2004 Feb; 93(2-3):197-202. PubMed ID: 14975547 [TBL] [Abstract][Full Text] [Related]
14. Relation of immediate decrease in ventricular septal strain after alcohol septal ablation for obstructive hypertrophic cardiomyopathy to long-term reduction in left ventricular outflow tract pressure gradient. van Ramshorst J; Mollema SA; Delgado V; van der Wall EE; Schalij MJ; Atsma DE; Bax JJ Am J Cardiol; 2009 Jun; 103(11):1592-7. PubMed ID: 19463521 [TBL] [Abstract][Full Text] [Related]
15. [Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy]. Qiao SB; Gao RL; You SJ; Yuan JS; Chen JL; Yang YJ Zhonghua Nei Ke Za Zhi; 2006 Mar; 45(3):210-2. PubMed ID: 16624154 [TBL] [Abstract][Full Text] [Related]
16. Time to significant gradient reduction following septal balloon occlusion predicts the magnitude of final gradient response during alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy. Almasood A; Garceau P; Woo A; Rakowski H; Schwartz L; Overgaard CB JACC Cardiovasc Interv; 2011 Sep; 4(9):1030-4. PubMed ID: 21939945 [TBL] [Abstract][Full Text] [Related]